Columbia, MD, announced that an independent, peer reviewed, clinical research study in which the level of cellular immune response measured prior to kidney transplantation using its proprietary ImmuKnow immune cell function test was found to identify patients that may be at risk for early acute transplant rejection and unstable kidney function in the first three months following transplantation.
Cylex says a statistically significant correlation was reported between high pre-transplant levels of cellular immune response, as measured using ImmuKnow immune cell function test, and early acute transplant rejection as well as unstable kidney function within the first 90 days following kidney transplantation.
today announced the publication of an independent, peer reviewed, clinical research study in which the level of cellular immune response measured prior to kidney transplantation using the Company's proprietary ImmuKnow(R) immune cell function test was found to identify patients that may be at risk for early acute transplant rejection
and unstable kidney function in the first three months following transplantation.
The primary clinical endpoint is defined as the occurrence of acute transplant rejection
, graft loss, or death within 6 months post-transplant.
ABX-CBL has been tested in various acute transplant rejection
indications in over 50 patients to date.
Acute transplant rejection
occurs when cells of the immune system recognize the transplanted organ as foreign and attack it as a potential threat.
A phase I/II study of BTI-322 for the treatment of acute transplant rejection
is currently underway at the Massachusetts General Hospital (MGH) under an Investigational New Drug (IND) application submitted by BioTransplant.
The Phase I/II study is designed to assess the tolerability and potential efficacy of BTI-322 in kidney transplant patients experiencing their first episode of biopsy-proven, acute transplant rejection
Donor kidney pre-treatment with Anti-CD45 may substantially reduce the dangers and added health-care costs associated with treating an acute transplant rejection
Donor kidney pre-treatment with LM-CD45 may substantially reduce the dangers and added healthcare costs associated with the treating an acute transplant rejection
This treatment appeared to diminish the frequency of acute transplant rejection
but elicited a human anti-mouse antibody (HAMA) immune response that restricted treatment to a two-week period.
We also expanded clinical trials of Oncolysin S, for the treatment of small-cell lung cancer, into Europe, and filed with the Food and Drug Administration to begin human testing of Oncolysin CD6, for the prevention of acute transplant rejection